Us Congress 2023-2024 Regular Session

Us Congress House Bill HB3375

Introduced
5/16/23  
Refer
5/16/23  

Caption

STOP Fentanyl Overdoses Act of 2023 Support, Treatment, and Overdoses Prevention of Fentanyl Overdoses Act of 2023

Impact

If enacted, this bill would significantly influence state laws surrounding drug surveillance and public health funding. By enhancing programs that secure data on drug-related overdoses and the circulation of illicit substances, states would be better equipped to respond to the opioid crisis. Additionally, it establishes grant support for overdose prevention services, encouraging the distribution of naloxone through community programs. This is particularly pertinent for areas that show higher rates of drug misuse and overdose deaths, leading to potentially more targeted and effective responses to the crisis at a local level.

Summary

House Bill 3375, titled the Support, Treatment, and Overdoses Prevention of Fentanyl Overdoses Act of 2023, aims to tackle the ongoing crisis of opioid addiction and overdoses, particularly those resulting from fentanyl and its analogs. The bill proposes a multifaceted approach by establishing grant programs for states and localities to enhance drug surveillance, improve access to opioid overdose reversal drugs like naloxone, and provide education on treatment options for substance use disorders. The legislation recognizes the urgent need to address the rising rates of overdose deaths linked to synthetic opioids, making it a critical intervention in public health efforts.

Contention

Despite its intentions, there are notable points of contention surrounding the bill. Critics may argue that the funding and programs created through the bill could lead to overreach by the government into individual choices related to substance use. Furthermore, the bill's reliance on community-based organizations for the distribution of naloxone and educational materials may face scrutiny regarding effectiveness and accessibility in diverse communities. It will be essential to monitor how the bill balances support for harm reduction while adhering to community needs and standards.

Companion Bills

US HB4005

Related Naloxone Affordability Act of 2023

Similar Bills

US HB4272

Stop Fentanyl Now Act of 2023

US HB568

SAFE Act Save Americans from the Fentanyl Emergency Act

US SB1619

Disrupt Fentanyl Trafficking Act of 2023

US HB3359

Disrupt Fentanyl Trafficking Act of 2023

US HB1758

SIFT Act of 2023 Stopping Illicit Fentanyl Trafficking Act of 2023

US HB2947

Justice Against Sponsors of Illicit Fentanyl Act of 2023

US SB389

Justice Against Sponsors of Illicit Fentanyl Act of 2023

US HB467

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This bill places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Additionally, the bill establishes a new, alternative registration process for schedule I research that is funded by the Department of Health and Human Services or the Department of Veterans Affairs or that is conducted under an investigative new drug exemption from the Food and Drug Administration. The bill also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.